Stock market today: Dow, S&P 500, Nasdaq futures climb as Wall Street digests July inflation report
Futures attached to the Dow Jones Industrial Average (YM=F) rose 0.6%. Those tied to the benchmark S&P 500 (ES=F), and the tech-heavy Nasdaq 100 (NQ=F) were both up around 0.7%.
The latest data from the Bureau of Labor Statistics showed that "core" inflation, which excludes volatile food and energy costs, rose 3.1% over the past year in July, ahead of June's 2.9% increase and indicating that rising goods inflation is no longer being offset by easing services inflation.
But on a headline basis, the Consumer Price Index (CPI) increased 2.7% year-over-year, matching June and coming in softer than economist expectations of a 2.8% rise.
The report was the first major piece of economic data to be released by the Bureau of Labor Statistics after Trump fired Erika McEntarfer as commissioner of the BLS earlier this month following the release of the July jobs report. Late Monday, Trump announced that he nominated E.J. Antoni, chief economist at the conservative Heritage Foundation, to lead the BLS.
In corporate news, Intel (INTC) stock jumped more than 2% in premarket trading on Tuesday after CEO Lip-Bu Tan met with President Trump, who had called for Tan's resignation last week.
After the meeting, Trump posted to Truth Social saying that he had met with Tan along with Secretary of Commerce Howard Lutnick and Secretary of the Treasury Scott Bessent. "The meeting was a very interesting one," the president wrote, adding, "His success and rise is an amazing story."
On Tuesday, reports said China urged local firms not to use Nvidia H20 chips, complicating Trump's bid to turn those sales into a US windfall. Trump also granted another 90-day pause on the most punishing tariffs on China as the two countries work toward a trade deal.
Read more: The latest on Trump's tariffs
Investors will get two more pulse checks on the state of the economy later this week, with the release of the Producer Price Index on Thursday and retail sales data on Friday.
"Core" price increases accelerate more than expected in July
Price increases accelerated more than expected in July.
The latest data from the Bureau of Labor Statistics showed that on a "core" basis, which strips out the more volatile costs of food and gas, consumer prices in increased 3.1% over the prior year in July, an increase from June's 2.9% and above economists' forecast for 3%.
Core prices climbed 0.3% over the prior month, ahead of June's 0.2% increase but in line with expectations.
The headline Consumer Price Index (CPI) showed prices increased 2.7% in July, unchanged from the month prior and below the 2.8% economists had expected. On a month-over-month basis, prices increased 0.2%, lower than the 0.3% seen the month prior.
Circle stock jumps on first earnings report since going public
Circle (CRCL) posted higher revenue and reserve income on Tuesday in its first quarterly report since its IPO in June, as circulation of its stablecoin USDC (USDC-USD) spread.
Circle stock rose 6% in premarket trading on Tuesday. Its total gains since going public are now 133%.
Reuters reports:
Read more here.
US small business optimism rebounds, but uncertainty clouds outlook
Reuters reports:
Read more here.
Good morning. Here's what's happening today.
Economic data: NFIB Small Business Optimism (July); Consumer Price Index (July); Real average hourly earnings (July)
Earnings: Circle (CRCL), Pony AI (PONY), On Holding (ONON), CoreWeave (CRWV), Rigetti (RGTI), Cava (CAVA)
Here are some of the biggest stories you may have missed overnight and early this morning:
July inflation report expected to show prices accelerated
Media musical chairs are reshaping the sports landscape
Earnings live: Circle pops on higher revenue in first earnings report
Intel stock rises after Trump praises CEO's 'amazing story'
China urges firms to shun Nvidia chips, trade truce extended
Musk accuses Apple of unfairly favoring OpenAI on iPhone
Google and IBM believe workable quantum computer is in sight
US small business optimism up but uncertainty clouds outlook
Switzerland wants binding Trump commitment on gold tariffs
Cannabis stocks soar as President Trump considers reclassifying marijuana
Tilray (TLRY) stock rose another 10% in premarket trading on Tuesday after soaring 41% on Monday amid speculation that President Trump may move to reclassify marijuana as a less dangerous drug.
The Canadian cannabis company traded hands at over $1 per share for the first time since February. Despite a 60% gain in the past month, however, shares are still off by 30% for the year.
Other cannabis stocks saw a major lift as well. Trulieve (TCNNF) gained 38% on Monday, Curaleaf (CURLF) was up 35%, Green Thumb Industries (GTBIF) added 19%, Aurora (ACB) increased 16%, and Canopy Growth (CGC) surged 26%.
On Friday, the Wall Street Journal reported that Trump told donors at a New Jersey fundraiser he was considering making marijuana a Schedule III drug, which would ease restrictions on the substance. Trump said he will make a final decision in the coming weeks.
"We're looking at reclassification and we'll make a determination over the next — I would say over the next few weeks, and that determination hopefully will be the right one," Trump said. "It's a very complicated subject."
Intel is still a disaster
Intel (INTC) is rallying premarket as Trump walked back his apparent hate for the company's CEO, Lip-Bu Tan, after meeting on Monday.
Don't be fooled by the price action, however.
This isn't the case like Apple (AAPL), where CEO Tim Cook kisses Trump's butt and the company is exempt from various tariffs. Intel is a fundamental disaster right now. People in the industry I talk to are unsure if the company will ever come back to a state of health, given 1) how fast AI chip development is occurring, and 2) how far behind Nvidia and AMD Intel is.
Intel's statement on the meeting:
"Earlier today, Mr. Tan had the honor of meeting with President Trump for a candid and constructive discussion on Intel's commitment to strengthening U.S. technology and manufacturing leadership. We appreciate the President's strong leadership to advance these critical priorities and look forward to working closely with him and his Administration as we restore this great American company."
Japan's Nikkei hits record high on tariff relief, tech rally
The Nikkei 225 (^N225) hit a record high Tuesday as easing US tariff fears boosted optimism, led by tech stocks and tariff relief.
Bloomberg News reports:
Read more here.
"Core" price increases accelerate more than expected in July
Price increases accelerated more than expected in July.
The latest data from the Bureau of Labor Statistics showed that on a "core" basis, which strips out the more volatile costs of food and gas, consumer prices in increased 3.1% over the prior year in July, an increase from June's 2.9% and above economists' forecast for 3%.
Core prices climbed 0.3% over the prior month, ahead of June's 0.2% increase but in line with expectations.
The headline Consumer Price Index (CPI) showed prices increased 2.7% in July, unchanged from the month prior and below the 2.8% economists had expected. On a month-over-month basis, prices increased 0.2%, lower than the 0.3% seen the month prior.
Price increases accelerated more than expected in July.
The latest data from the Bureau of Labor Statistics showed that on a "core" basis, which strips out the more volatile costs of food and gas, consumer prices in increased 3.1% over the prior year in July, an increase from June's 2.9% and above economists' forecast for 3%.
Core prices climbed 0.3% over the prior month, ahead of June's 0.2% increase but in line with expectations.
The headline Consumer Price Index (CPI) showed prices increased 2.7% in July, unchanged from the month prior and below the 2.8% economists had expected. On a month-over-month basis, prices increased 0.2%, lower than the 0.3% seen the month prior.
Circle stock jumps on first earnings report since going public
Circle (CRCL) posted higher revenue and reserve income on Tuesday in its first quarterly report since its IPO in June, as circulation of its stablecoin USDC (USDC-USD) spread.
Circle stock rose 6% in premarket trading on Tuesday. Its total gains since going public are now 133%.
Reuters reports:
Read more here.
Circle (CRCL) posted higher revenue and reserve income on Tuesday in its first quarterly report since its IPO in June, as circulation of its stablecoin USDC (USDC-USD) spread.
Circle stock rose 6% in premarket trading on Tuesday. Its total gains since going public are now 133%.
Reuters reports:
Read more here.
US small business optimism rebounds, but uncertainty clouds outlook
Reuters reports:
Read more here.
Reuters reports:
Read more here.
Good morning. Here's what's happening today.
Economic data: NFIB Small Business Optimism (July); Consumer Price Index (July); Real average hourly earnings (July)
Earnings: Circle (CRCL), Pony AI (PONY), On Holding (ONON), CoreWeave (CRWV), Rigetti (RGTI), Cava (CAVA)
Here are some of the biggest stories you may have missed overnight and early this morning:
July inflation report expected to show prices accelerated
Media musical chairs are reshaping the sports landscape
Earnings live: Circle pops on higher revenue in first earnings report
Intel stock rises after Trump praises CEO's 'amazing story'
China urges firms to shun Nvidia chips, trade truce extended
Musk accuses Apple of unfairly favoring OpenAI on iPhone
Google and IBM believe workable quantum computer is in sight
US small business optimism up but uncertainty clouds outlook
Switzerland wants binding Trump commitment on gold tariffs
Economic data: NFIB Small Business Optimism (July); Consumer Price Index (July); Real average hourly earnings (July)
Earnings: Circle (CRCL), Pony AI (PONY), On Holding (ONON), CoreWeave (CRWV), Rigetti (RGTI), Cava (CAVA)
Here are some of the biggest stories you may have missed overnight and early this morning:
July inflation report expected to show prices accelerated
Media musical chairs are reshaping the sports landscape
Earnings live: Circle pops on higher revenue in first earnings report
Intel stock rises after Trump praises CEO's 'amazing story'
China urges firms to shun Nvidia chips, trade truce extended
Musk accuses Apple of unfairly favoring OpenAI on iPhone
Google and IBM believe workable quantum computer is in sight
US small business optimism up but uncertainty clouds outlook
Switzerland wants binding Trump commitment on gold tariffs
Cannabis stocks soar as President Trump considers reclassifying marijuana
Tilray (TLRY) stock rose another 10% in premarket trading on Tuesday after soaring 41% on Monday amid speculation that President Trump may move to reclassify marijuana as a less dangerous drug.
The Canadian cannabis company traded hands at over $1 per share for the first time since February. Despite a 60% gain in the past month, however, shares are still off by 30% for the year.
Other cannabis stocks saw a major lift as well. Trulieve (TCNNF) gained 38% on Monday, Curaleaf (CURLF) was up 35%, Green Thumb Industries (GTBIF) added 19%, Aurora (ACB) increased 16%, and Canopy Growth (CGC) surged 26%.
On Friday, the Wall Street Journal reported that Trump told donors at a New Jersey fundraiser he was considering making marijuana a Schedule III drug, which would ease restrictions on the substance. Trump said he will make a final decision in the coming weeks.
"We're looking at reclassification and we'll make a determination over the next — I would say over the next few weeks, and that determination hopefully will be the right one," Trump said. "It's a very complicated subject."
Tilray (TLRY) stock rose another 10% in premarket trading on Tuesday after soaring 41% on Monday amid speculation that President Trump may move to reclassify marijuana as a less dangerous drug.
The Canadian cannabis company traded hands at over $1 per share for the first time since February. Despite a 60% gain in the past month, however, shares are still off by 30% for the year.
Other cannabis stocks saw a major lift as well. Trulieve (TCNNF) gained 38% on Monday, Curaleaf (CURLF) was up 35%, Green Thumb Industries (GTBIF) added 19%, Aurora (ACB) increased 16%, and Canopy Growth (CGC) surged 26%.
On Friday, the Wall Street Journal reported that Trump told donors at a New Jersey fundraiser he was considering making marijuana a Schedule III drug, which would ease restrictions on the substance. Trump said he will make a final decision in the coming weeks.
"We're looking at reclassification and we'll make a determination over the next — I would say over the next few weeks, and that determination hopefully will be the right one," Trump said. "It's a very complicated subject."
Intel is still a disaster
Intel (INTC) is rallying premarket as Trump walked back his apparent hate for the company's CEO, Lip-Bu Tan, after meeting on Monday.
Don't be fooled by the price action, however.
This isn't the case like Apple (AAPL), where CEO Tim Cook kisses Trump's butt and the company is exempt from various tariffs. Intel is a fundamental disaster right now. People in the industry I talk to are unsure if the company will ever come back to a state of health, given 1) how fast AI chip development is occurring, and 2) how far behind Nvidia and AMD Intel is.
Intel's statement on the meeting:
"Earlier today, Mr. Tan had the honor of meeting with President Trump for a candid and constructive discussion on Intel's commitment to strengthening U.S. technology and manufacturing leadership. We appreciate the President's strong leadership to advance these critical priorities and look forward to working closely with him and his Administration as we restore this great American company."
Intel (INTC) is rallying premarket as Trump walked back his apparent hate for the company's CEO, Lip-Bu Tan, after meeting on Monday.
Don't be fooled by the price action, however.
This isn't the case like Apple (AAPL), where CEO Tim Cook kisses Trump's butt and the company is exempt from various tariffs. Intel is a fundamental disaster right now. People in the industry I talk to are unsure if the company will ever come back to a state of health, given 1) how fast AI chip development is occurring, and 2) how far behind Nvidia and AMD Intel is.
Intel's statement on the meeting:
"Earlier today, Mr. Tan had the honor of meeting with President Trump for a candid and constructive discussion on Intel's commitment to strengthening U.S. technology and manufacturing leadership. We appreciate the President's strong leadership to advance these critical priorities and look forward to working closely with him and his Administration as we restore this great American company."
Japan's Nikkei hits record high on tariff relief, tech rally
The Nikkei 225 (^N225) hit a record high Tuesday as easing US tariff fears boosted optimism, led by tech stocks and tariff relief.
Bloomberg News reports:
Read more here.
The Nikkei 225 (^N225) hit a record high Tuesday as easing US tariff fears boosted optimism, led by tech stocks and tariff relief.
Bloomberg News reports:
Read more here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Better Technology Stock: Nvidia vs. Palantir
Key Points Nvidia is now the most valuable publicly traded company in the world, and all signs point to another great earnings report this month. Palantir Technologies is the fastest-growing company in the S&P 500. 10 stocks we like better than Nvidia › Semiconductor giant Nvidia (NASDAQ: NVDA) and artificial intelligence (AI) kingpin Palantir Technologies (NASDAQ: PLTR) are two of the most compelling technology stocks in the market. Nvidia harnessed demand for its graphics processing units (GPUs) to become the biggest company in the world, with a $4.4 trillion market capitalization. Palantir, meanwhile, is using its artificial intelligence platform to fundamentally change how governments and commercial businesses operate. The stock is up more than 500% in the last year and is the best-performing stock in the S&P 500. In my view, you can't go wrong with either of these tech stocks. But in a one-on-one matchup, which comes out on top? Let's look at both companies before rendering a verdict. Nvidia Nvidia's GPUs are the engine behind this mammoth company. While they used to be best known for providing the graphics in computers, now GPUs are commonly used by companies that are building massive data centers to run artificial intelligence-powered platforms, including large language models needed for generative AI. Nvidia has the lion's share of this business, with Jon Peddie Research estimating that it has roughly 92% of the market share. And as Nvidia is expecting spending on data centers to accelerate from $250 billion in 2023 to $1 trillion annually by 2028, there's a massive opportunity at hand. In addition, major tech companies like Microsoft, Alphabet, and Meta Platforms are spending heavily and are even increasing their capital expenditure spending on their data centers. That's why I'm expecting a solid earnings report from Nvidia when it reports its earnings for the current quarter, and why I'm expecting the stock to pop yet again after the numbers are released. Palantir Technologies Palantir got its start a little more than 20 years ago as a data mining company to provide real-time analytics and insights. As a government contractor, it's long been valued by the military for its analytic technology that helps commanders make real-time decisions in battle. To the public eye, Palantir largely flew under the radar for years until in 2011, when it was credited for helping U.S. forces find and eliminate Sept. 11 mastermind Osama bin Laden. Palantir works by drawing information from many sources, such as satellite imagery. By sifting through and digesting that information, it can perform instantaneous analysis that can help governments function. According to its CEO, Alex Karp, "Palantir was founded on the belief that the United States, its allies, and partners should harness the most advanced technical capabilities for their defense and prosperity." As its capabilities expanded through the launch of its generative AI-powered Artificial Intelligence Platform (AIP), Palantir is quickly bringing in additional non-military government contracts. It has new contracts with the Federal Aviation Administration, the Centers for Disease Control and Prevention, the State Department, and the Internal Revenue Service. In the company's just-released second quarter earnings report, U.S. government revenue increased 53% in the last year, reaching $426 million. Commercial revenue is growing even faster, up 93% in the second quarter on a year-over-year basis and reaching $306 million. Clients include Walgreens Boots Alliance, AT&T, General Mills, United Airlines, and others, and Palantir is doing everything from making manufacturing more efficient to managing supply chains and helping companies scale. Palantir closed 157 deals in the second quarter valued at more than $1 million, with 66 of them more than $5 million and 42 of them at least $10 million. As more companies bring Palantir's platform online and share how they are improving their businesses, Palantir's platform will become a must-have for many institutions. The verdict I'm not gonna lie. This is a tough one. I love both of these companies, and I think both are destined to increase. But if I have to choose one, then the valuations of both companies will break the tie. At the time of this writing, Nvidia is richly valued both in its price-to-earnings (P/E) ratio of 59 and its forward P/E of 42, but Palantir comes in at an unhealthy 623 and 288, respectively. The price-to-sales ratio, which compares market capitalization to revenue, is arguably an even more accurate measurement as both of these companies are pouring profits back into the business. And Nvidia is by far the strongest there, too. So, my winner in this hypothetical battle is Nvidia by a nose. But both stocks are great ones to have, and they'll both anchor my portfolio for the foreseeable future. Should you buy stock in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Patrick Sanders has positions in Nvidia and Palantir Technologies. The Motley Fool has positions in and recommends Alphabet, Meta Platforms, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Better Technology Stock: Nvidia vs. Palantir was originally published by The Motley Fool Sign in to access your portfolio
New York Times
28 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
New York Post
an hour ago
- New York Post
Ukrainian sniper breaks world record with 13,000-foot kill shot against Russian forces: report
A Ukrainian sniper unit on Thursday reportedly broke the world record for the longest confirmed sniper kill, eliminating Russian troops from a distance of more than 13,000 feet. The shot, fired by a Ukrainian-produced rifle and aided by artificial intelligence and drone guidance, left two Russian soldiers dead in the area of Pokrovsk, Ukraine, the Kyiv Post reported. 'The record-breaking shot was made on Aug. 14, 2025, using artificial intelligence under the guidance of [an unmanned aerial vehicle] complex with a 14.5 mm alligator rifle,' said military journalist Yuri Butusov, according to the Kyiv Post. The shooting took place amid increased Russian attacks in the area surrounding Pokrovsk, which was once a city with more than 60,000 residents, the Post reported. The previous world record belonged to a 58-year-old Ukrainian sniper who eliminated a target from a distance of around 12,400 feet, the outlet added. The record-breaking shot reportedly took place a day before President Donald Trump's closely-watched summit Friday with Russian President Vladimir Putin. 3 A Ukrainian soldier in the sniper unit of the 108th Territorial Defense Brigade readies a rifle during training on Nov. 4, 2023. Anadolu via Getty Images 3 The previous world record was held by another Ukrainian sniper who took out a Russian soldier from nearly 2½ miles away with a high-tech rifle known as 'Horizon's Lord.' SBU 3 Ukrainian soldiers take part in a sniper shooting exercise at a training facility outside Kyiv on Nov. 21, 2023. AFP via Getty Images Putin, who spoke first in a joint press conference held by the two world leaders, described the talks as a 'constructive atmosphere of mutual respect.' Ukrainian President Volodymyr Zelensky is scheduled to meet with Trump in Washington, DC, Monday. Zelensky said in a post on X that he and Trump will 'discuss all of the details regarding ending the killing and the war.'
